Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks

被引:32
作者
Sabourin, M
Nitiss, JL
Nitiss, KC
Tatebayashi, K
Ikeda, H
Osheroff, N
机构
[1] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Med Hematol Oncol, Nashville, TN 37232 USA
[3] St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38101 USA
[4] Univ Tokyo, Inst Med Sci, Div Mol Cell Signaling, Minato Ku, Tokyo 1088639, Japan
[5] Medinet Inc, Inst Med Sci, Kouhoku Ku, Yokohama, Kanagawa 2220033, Japan
关键词
D O I
10.1093/nar/gkg497
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Topoisomerase II is a ubiquitous enzyme that removes knots and tangles from the genetic material by generating transient double-strand DNA breaks. While the enzyme cannot perform its essential cellular functions without cleaving DNA, this scission activity is inherently dangerous to chromosomal integrity. In fact, etoposide and other clinically important anticancer drugs kill cells by increasing levels of topoisomerase II-mediated DNA breaks. Cells rely heavily on recombination to repair double-strand DNA breaks, but the specific pathways used to repair topoisomerase II-generated DNA damage have not been defined. Therefore, Saccharomyces cerevisiae was used as a model system to delineate the recombination pathways that repair DNA breaks generated by topoisomerase II. Yeast cells that expressed wild-type or a drug-hypersensitive mutant topoisomerase II or overexpressed the wild-type enzyme were examined. Based on cytotoxicity and recombination induced by etoposide in different repair-deficient genetic backgrounds, double-strand DNA breaks generated by topoisomerase II appear to be repaired primarily by the single-strand invasion pathway of homologous recombination. Non-homologous end joining also was triggered by etoposide treatment, but this pathway was considerably less active than single-strand invasion and did not contribute significantly to cell survival in S.cerevisiae.
引用
收藏
页码:4373 / 4384
页数:12
相关论文
共 103 条
[21]  
FELDMANN H, 1993, J BIOL CHEM, V268, P12895
[22]   Secondary leukemias induced by topoisomerase-targeted drugs [J].
Felix, CA .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3) :233-255
[23]   Leukemias related to treatment with DNA topoisomerase II inhibitors [J].
Felix, CA .
MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 36 (05) :525-535
[24]   Association of CYP3A4 genotype with treatment-related leukemia [J].
Felix, CA ;
Walker, AH ;
Lange, BJ ;
Williams, TM ;
Winick, NJ ;
Cheung, NKV ;
Lovett, BD ;
Nowell, PC ;
Blair, IA ;
Rebbeck, TR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (22) :13176-13181
[25]   Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice [J].
Fortune, JM ;
Osheroff, N .
PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY, VOL 64, 2000, 64 :221-253
[26]   Partners and pathways - repairing a double-strand break [J].
Haber, JE .
TRENDS IN GENETICS, 2000, 16 (06) :259-264
[27]   Recombination: a frank view of exchanges and vice versa [J].
Haber, JE .
CURRENT OPINION IN CELL BIOLOGY, 2000, 12 (03) :286-292
[28]   SMALL DELETION AND INSERTION MUTATIONS INDUCED BY THE TOPOISOMERASE-II INHIBITOR TENIPOSIDE IN CHO CELLS AND COMPARISON WITH SITES OF DRUG-STIMULATED DNA CLEAVAGE INVITRO [J].
HAN, YH ;
AUSTIN, MJF ;
POMMIER, Y ;
POVIRK, LF .
JOURNAL OF MOLECULAR BIOLOGY, 1993, 229 (01) :52-66
[29]   Clinical applications of anticancer drugs targeted to topoisomerase II [J].
Hande, KR .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3) :173-184
[30]  
HOLM C, 1989, CANCER RES, V49, P6365